Inhaled Interferon and Diffusion Capacity in Idiopathic Pulmonary Fibrosis (IPF).

  title={Inhaled Interferon and Diffusion Capacity in Idiopathic Pulmonary Fibrosis (IPF).},
  author={Shibu Skaria and Jie Yang and Rany Condos and Gerald C. Smaldone},
  journal={Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG},
  volume={32 1},
BACKGROUND Using data from a previously reported phase 2 safety trial, testing inhaled interferon gamma (IFN-γ) for IPF, we analyzed effects on full pulmonary function tests (PFTs) for efficacy before and after therapy and designed a randomized controlled trial of inhaled IFN-γ to treat IPF. METHODS Ten patients with IPF had received inhaled IFN-γ (Actimmune, InterMune) for 80 weeks. Full PFTs were available 20-50 weeks before Rx and monthly during Rx. Eighty-nine observations were used in… CONTINUE READING

From This Paper

Figures and tables from this paper.


Publications citing this paper.


Publications referenced by this paper.
Showing 1-10 of 23 references

Idiopathic pulmonary fibrosis

Nature Reviews Disease Primers • 2017

The treatment of idiopathic pulmonary fibrosis

HV Woodcock, TM Mahr
F1000Prime Reports • 2014

Delivery and safety of inhaled interferon-γ in idiopathic pulmonary fibrosis.

Journal of aerosol medicine and pulmonary drug delivery • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…